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A Randomized Trial Comparing Immediate versus Delayed
Treatment of Anemia with Once-Weekly Epoetin Alfa in
Patients with Non-small Cell Lung Cancer Scheduled to
Receive First-Line Chemotherapy
Jeffrey Crawford, MD,* Francisco Robert, MD,† Michael C. Perry, MD,‡ Chandra Belani, MD,§
and Denise Williams, MD, for the Anemia Prevention in NSCLC Group
Introduction: This study evaluated the safety/efficacy of once-
weekly (QW) epoetin alfa measured by quality of life (QOL),
hemoglobin (Hb), transfusion incidence, tumor response, and sur-
vival in patients with chemotherapy-naı¨ve, advanced non-small cell
lung cancer (NSCLC).
Methods: Stage IIIB/IV NSCLC patients with Hb 11 to 15 g/dl
scheduled for at least 8 weeks of first-line chemotherapy were
randomized to subcutaneously receive 40,000 U of epoetin alfa QW
at chemotherapy initiation (immediate) or no epoetin alfa unless Hb
decreased to 10 g/dl (delayed). The primary efficacy variable was
change in QOL for immediate versus delayed intervention. Target
accrual was 320 patients.
Results: The study was terminated early because of slow accrual; of
216 patients enrolled, 211 were evaluable for efficacy. Hb was
maintained in the immediate group, but it decreased in the delayed
group (12.9 versus 11.6 g/dl final values, respectively). Numerically,
fewer immediate patients required transfusions versus delayed pa-
tients. Mean QOL scores, modestly declining in both groups from
baseline to final measurement, were not significantly different be-
tween groups. Tumor response and median overall survival were
similar between groups. Epoetin alfa was well tolerated, with a
similar thrombovascular event rate between groups.
Conclusion: Epoetin alfa in subcutaneous doses of 40,000 U QW,
given immediately at chemotherapy initiation for advanced NSCLC,
was well tolerated, and it effectively maintained Hb, leading to a
reduced transfusion incidence versus delayed epoetin alfa. Overall
QOL scores were higher than typical in this population, decreasing
slightly during treatment in both groups. Overall survival was
similar between groups, with no evidence of a negative effect by
early epoetin alfa intervention.
Key Words: Epoetin alfa, Chemotherapy-related anemia, Non-
small-cell lung cancer.
(J Thorac Oncol. 2007;2: 210–220)
The presence and severity of anemia in patients with lungcancer depend on disease stage and on the duration, type,
and intensity of cytotoxic chemotherapy or radiologic treat-
ment.1 Nearly all patients with advanced non-small cell lung
cancer (NSCLC) develop mild to moderate anemia (hemo-
globin [Hb] 8 to 12 g/dl), and up to 55% develop severe or
life-threatening anemia (Hb 8 g/dl).2,3 In addition, patients
with NSCLC commonly have comorbidities such as cardio-
vascular disease and chronic obstructive pulmonary dis-
ease,4,5 which may exacerbate the symptoms of anemia and
reduce patients’ ability to tolerate decreases in Hb during
chemotherapy. Hemoglobin levels 12 g/dl have been asso-
ciated with suboptimal quality of life (QOL) in patients with
cancer receiving chemotherapy,6,7 and a statistically signifi-
cant and clinically meaningful impairment in QOL (measured
by the Functional Assessment of Cancer Therapy–Lung
[FACT-L] questionnaire) has been documented in patients
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with NSCLC receiving chemotherapy without erythropoietic
support.8,9 Further, a recent retrospective analysis of data
from five trials conducted by the Cancer and Leukemia Group
B has demonstrated that baseline Hb is a significant predictor
of survival in NSCLC.10
Guidelines jointly issued by the American Society of
Hematology and the American Society of Clinical Oncology
recommend epoetin alfa as a treatment option for patients
with chemotherapy-related anemia and Hb 10 g/dl,11 and
the National Comprehensive Cancer Network guidelines for
cancer- and treatment-related anemia recommend considering
therapy with an erythropoietic agent for Hb 11 g/dl.12 In
patients with cancer and moderate anemia who are undergo-
ing chemotherapy and receiving epoetin alfa once weekly
(QW) or three times weekly (TIW), a significant correlation
has been found between Hb increase and improved
QOL.5,13–16 In patients with lung cancer and moderate anemia
who are receiving chemotherapy, treatment with 40,000 U of
epoetin alfa QW administered subcutaneously or 150 U/kg
TIW reduces transfusion use, increases Hb, and leads to
statistically and clinically significant improvements in
QOL.17 Moreover, recent open-label studies in patients with
breast cancer18,19 and hematologic malignancies20,21 have
shown that QW epoetin alfa therapy in patients with cancer
and mild anemia (mean baseline Hb levels 11 g/dl) main-
tains Hb and prevents QOL deterioration during chemother-
apy. Other studies investigating earlier treatment with epoetin
alfa in patients with breast cancer receiving chemotherapy
also have reported encouraging results regarding hematologic
and QOL improvement.22,23
However, after this study was conducted, two random-
ized trials evaluating the use of erythropoietic agents to
maintain Hb levels within the normal range during anticancer
treatment showed a decrease in survival among patients
receiving erythropoietic therapy compared with control
groups.24,25 Both studies were thoroughly analyzed, after
which the U.S. Food and Drug Administration requested a
review by its Oncology Drug Advisory Committee of all
company-sponsored trial results for three erythropoietic
agents (epoetin alfa, epoetin beta, and darbepoetin alfa).26
These analyses did not suggest a negative effect on survival
when erythropoietic agents were administered according to
Food and Drug Administration guidelines, nor did they pro-
vide a clear explanation for the negative study results. In fact,
the Oncology Drug Advisory Committee endorsed preclinical
studies and clinical trials to further investigate the issue with
respect to disease outcome. Our trial was designed to evaluate
the safety and clinical outcomes of preemptive treatment with
epoetin alfa at the start of first-line chemotherapy compared
with later treatment of moderate anemia.
MATERIALS AND METHODS
Study Design
This was a randomized, open-label, multicenter, 16-
week study conducted at 29 sites in the United States between
September 1999 and December 2001. The study protocol and
amendments were reviewed by an independent institutional
review board at each site or by the central institutional review
board used by the site. Patients who met all inclusion/
exclusion criteria were randomized in a 1:1 ratio to receive
either epoetin alfa 40,000 U QW initiated at the start of
chemotherapy (immediate epoetin alfa group) or no epoetin
alfa unless Hb declined to 10 g/dl during chemotherapy
(delayed group) (Figure 1). Supplemental iron was recom-
mended for serum ferritin 100 ng/ml or transferrin satura-
tion 20%. Patients were permitted to receive red blood cell
(RBC) transfusions during the study according to the treat-
ment guidelines at each site.
Patients
Patient eligibility criteria were age 18 years; histo-
logically confirmed, chemotherapy-naı¨ve stage IIIB/IV
NSCLC; Hb 11 g/dl to 15 g/dl (no RBC transfusions
within 30 days of baseline Hb measurement); scheduled to
receive at least 8 weeks of chemotherapy (experimental
chemotherapy regimens and radiotherapy permitted); Eastern
Cooperative Oncology Group (ECOG) performance status 0
to 2; negative pregnancy test and use of effective contracep-
tion; and ability to provide written informed consent. Patients
were excluded for the following reasons: receipt of more than
one dose of chemotherapy for lung cancer within 7 days of
study initiation; active second primary malignancy or other
malignancy within the preceding 3 years (other than dermal
basal cell carcinoma or cervical cancer in situ); any medical
condition precluding administration of chemotherapy; symp-
tomatic brain metastases; current or previous receipt of inter-
feron or interleukin therapy; pregnancy or lactation; uncon-
trolled hypertension; hypersensitivity to human albumin or
mammalian cell-derived products; or treatment with epoetin
alfa or any investigational form of erythropoietin within the
previous 6 months.
Patients provided their written consent to participate in
the study at the baseline visit after having been informed
FIGURE 1. Treatment schema. SC, subcutaneously; QW,
once weekly; Hb, hemoglobin; 2, decrease; 1, increase.
Journal of Thoracic Oncology • Volume 2, Number 3, March 2007 Early Intervention with Epoetin Alfa in NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer 211
about the nature and purpose of the study, participation and
termination conditions, and risks and benefits of treatment.
Assessments
Assessments of QOL included the Linear Analog Scale
Assessment (LASA), Functional Assessment of Cancer Ther-
apy–General (FACT-G), Functional Assessment of Cancer
Therapy–Anemia (FACT-An), Functional Assessment of
Cancer Therapy–Lung Cancer (FACT-L), and the Brief Fa-
tigue Inventory (BFI). The LASA is a 100-mm linear ana-
logue scale on which patients rate their energy level, ability to
perform daily activities, and overall QOL during the previous
week. A higher score reflects better QOL, and a change of
more than 8.7 to 9.8 mm (depending on the domain) in the
LASA score is considered clinically meaningful.25 The
FACT-G is a core self-report questionnaire that assesses 27
cancer-related items in four categories (physical, social/fam-
ily, emotional, and functional well-being). Responses to in-
dividual questions are scored on a five-point scale, and higher
scores reflect better well-being. The FACT-An comprises the
FACT-G plus a 20-item anemia-specific subscale. The
FACT-L comprises the FACT-G plus 10 lung cancer–specific
items.27 The BFI is a questionnaire designed to assess the
patient’s level of fatigue and its effect on QOL.28,29 An
increase in score reflects an increase in the patient’s percep-
tion of fatigue.
The following assessments were completed within 14
days of study entry: QOL (within 7 days), ECOG perfor-
mance status, demographics, histological or cytological con-
firmation of NSCLC, tumor stage, transfusion history, clini-
cal laboratory tests, and details of scheduled chemotherapy.
Patients were evaluated weekly for Hb, hematocrit, transfu-
sion requirements, and blood pressure. Other study evalua-
tions including QOL, ECOG performance status, clinical
laboratory measurements, body weight, change in chemother-
apy, adverse events, and tumor response were scheduled
according to the patient’s chemotherapy cycle duration—
either every 3 weeks or every 4 weeks (for patients on
weekly, every-2-weeks, or every-4-weeks chemotherapy cy-
cles). Patients were blinded to study-related test results until
after the QOL assessments were completed. Survival was
recorded as duration of life from study entry to death; for
living patients, it was censored at the date of last contact. The
duration of retrospective follow-up was approximately 1.5
years after the last patient completed the study. Safety was
evaluated by monitoring adverse events, clinical laboratory
tests, and blood pressure at each clinic visit.
Statistics
The original sample size for the study was 320 patients
(160 patients per arm), which would provide 80% power to
detect a difference between the treatment groups on the basis
of the assumption that the mean change in LASA score of
patients receiving immediate epoetin alfa would be 10 mm
higher than that of patients randomized to the delayed epoetin
alfa group with an SD of 30 mm at the midpoint in the study
(week 9 for the every-4-weeks chemotherapy stratum and week
10 for the every-3-weeks chemotherapy stratum). It is generally
accepted that a change in LASA score of at least 10 mm is
clinically meaningful.6 The primary efficacy variables were the
comparisons of mean change in LASA score from baseline to
week 9/10 and from baseline to study end in the immediate
epoetin alfa versus delayed groups. The secondary efficacy
variable was the magnitude of change in LASA score (i.e.,10
mm or 10 mm) from baseline to study end in the immediate
epoetin alfa group. Other efficacy variables included changes
from baseline for FACT-L, FACT-G, FACT-An, BFI, Hb,
transfusions, tumor response, and overall survival.
The safety population was to comprise all patients who
were randomized (one patient randomized to immediate epo-
etin alfa who was later determined to be ineligible and
discontinued the study prior to treatment, was excluded from
the safety population). Efficacy analyses were performed on
the modified intent-to-treat population, which included all
randomized patients who had at least one postbaseline effi-
cacy evaluation. Missing Hb and QOL data were handled
using the last-observation-carried-forward approach. Data for
the delayed group were analyzed as a whole, irrespective of
whether a patient received epoetin alfa for declining Hb.
However, a secondary planned analysis (referred to as a
censored analysis) was also performed on the delayed group,
in which all measurements taken once a patient received a
dose of epoetin alfa were censored (excluded) to allow for
analyses that excluded the effects of epoetin alfa therapy in
this group. No data were censored for tumor response, sur-
vival, or safety analyses.
Differences between the treatment groups for linear
efficacy measures (LASA scores, FACT-L, FACT-G, FACT-
An, BFI, and Hb) were assessed by ANOVA models that
included factor for treatment group, chemotherapy stratum
(every 3 weeks versus every 4 weeks), treatment group-by-
chemotherapy strata interaction, and study site. Within each
group, the significance of the change from baseline to each of
the postbaseline visits was determined using a paired t-test.
Categorical efficacy assessments (tumor response and num-
ber of transfusions) were analyzed using the Cochran–Man-
tel–Haenszel test. Time to tumor progression and time to
death were analyzed using Kaplan–Meier survival methods.
Treatment groups were compared using a Cox regression
analysis that included terms for treatment group, chemother-
apy strata, and treatment group-by-chemotherapy strata inter-
action in the model. All statistical tests were two tailed and
were performed at the 5% significance level.
Post hoc analyses were conducted to better characterize
the relationship between Hb levels and the occurrence of
thrombovascular events (TVEs) in the immediate epoetin alfa
and delayed groups, and to determine time to Hb 10 g/dl in
both of these groups. Additional post hoc analyses also
assessed Hb over time, tumor response, and the incidence of
TVEs specifically in delayed patients subsequently receiving
epoetin alfa.
RESULTS
Patients
The study had a targeted accrual of 320 patients and
was terminated early because of slow enrollment, partly
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because many patients had Hb levels 11 g/dl at screening.
A total of 216 patients from 29 sites were enrolled. The
disposition of patients is shown in Figure 2. Forty-eight
(46%) patients in the delayed group received epoetin alfa for
declining Hb. Of note, seven patients in the delayed group
whose Hb decreased to 10 g/dl (range, 8.2 to 9.9 g/dl) did
not receive epoetin alfa. Seven additional patients in the
delayed group received epoetin alfa despite having an Hb
10 g/dl (range, 10.6 to 14.3 g/dl).
Demographic and baseline characteristics for the mod-
ified intent-to-treat population are presented in Table 1. The
only significant difference between groups was a larger propor-
tion of patients with a baseline ECOG performance status of 2 in
the delayed group versus the immediate epoetin alfa group. In
addition, baseline scores for FACT-G and FACT-L in the
immediate epoetin alfa group (78.8 and 100.7, respectively)
were significantly higher (p  0.05) than in the delayed group
(73.8 and 95.4, respectively). Approximately 80% of patients
received platinum-containing chemotherapy, and the mean du-
ration of chemotherapy was 10.6 weeks in each group.
Epoetin Alfa Dosing
For the 48 (46%) patients in the delayed group who
received epoetin alfa, the median time to first dose was 5.7
FIGURE 2. Patient disposition. *One patient
was randomized to immediate epoetin alfa but
did not meet eligibility criteria and was ex-
cluded from the study before receiving treat-
ment. †Modified intent-to-treat analysis; pa-
tients who were randomized and had at least
one postbaseline efficacy evaluation. ‡Includes
seven patients who received epoetin alfa de-
spite having Hb 10 g/dl. §A patient was con-
sidered to have completed the study at the
week 16 visit after completing the final study
evaluations.
TABLE 1. Demographic and Baseline Characteristics (Modified Intent to Treat,
N  211)
Characteristic
Immediate
Epoetin Alfa
(n  106)
Delayed
(n  105)
Age in years, mean  SD 62.3  11.0 62.7  10.6
Gender, n (%)
Male 67 (63.2) 57 (54.3)
Female 39 (36.8) 48 (45.7)
Race, n (%)
Caucasian 73 (68.9) 86 (81.9)
Black 25 (23.6) 14 (13.3)
Asian 5 (4.7) 2 (1.9)
Other 3 (2.8) 3 (2.9)
ECOG performance status, n (%)*
0–1 101 (95.3) 84 (80.0)
2 6 (5.7) 21 (20.0)†
LASA overall QOL score in millimeters, mean  SD 61.2  24.0 (n  99) 54.6  28.3 (n  95)
Hb in grams per deciliter, mean  SD 13.1  1.0 13.0  1.2
Received platinum-containing chemotherapy, n (%) 85 (80.2) 82 (78.1)
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; LASA, linear analogue scale assessment; QOL,
quality of life; Hb, hemoglobin.
*p  0.009 for epoetin alfa group versus delayed group (ANOVA with treatment group, strata, treatment by strata
interaction, and study site included in the model).
†Includes one patient with ECOG performance status 3.
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weeks. The majority of patients did not require dose escala-
tion (immediate, 79.2%; delayed patients who received epo-
etin alfa, 70.8%). Dose was reduced from 40,000 U subcu-
taneously QW to 20,000 U subcutaneously QW in 11.3% of
patients in the immediate epoetin alfa group and in 4.2% of
delayed patients who received epoetin alfa. Of 16 patients
who had an Hb 15 g/dl on two consecutive evaluations, 12
had their doses reduced, three had doses withheld, and one
had no dose adjustment.
Quality of Life
Mean LASA Overall QOL scores at baseline, week
9/10, and final measurement are presented in Figure 3. QOL
declined in both the immediate epoetin alfa and the delayed
groups, and the changes were not significantly different
between groups. Analysis of patients with both baseline and
week 16 QOL assessments found that LASA overall QOL
decreased by a mean of 5.3 mm (n  90) from baseline to
study end in the immediate epoetin alfa group and by a mean
of 6.0 mm (n  87) in the delayed group (censored analysis,
mean of 8.0 mm [n  73]). For the following tertiary QOL
endpoints, only censored analysis of the delayed group was
performed. LASA energy, LASA activity, FACT-G, and
FACT-L scores declined, but not significantly, in the imme-
diate epoetin alfa and delayed groups from baseline to study
end; mean changes from baseline were not significantly
different between treatment groups. In the immediate epoetin
alfa group, FACT-An subscale scores declined significantly
from baseline to study end (mean change from baseline,
7.7; p  0.0187). In both treatment groups, mean BFI
scores declined significantly from baseline to study end
(immediate epoetin alfa group, 3.2, p  0.0198; censored
delayed group, 3.3, p  0.0345).
Hematologic Outcomes
Hemoglobin was maintained throughout the study in
the immediate epoetin alfa group (mean final Hb, 12.9 g/dl)
but decreased from baseline in the delayed group (mean final
Hb, 11.6 g/dl) (Figure 4). In the delayed group, mean Hb
increased from week 8 to week 16, as an increasing number
of patients commenced epoetin alfa therapy for declining Hb.
In the censored analysis of the delayed group (which ex-
cluded the effects of epoetin alfa), Hb levels steadily declined
to a final value of 10.8 g/dl. Hemoglobin decreased to 10
g/dl in 44% of patients in the delayed group and in 18% of
patients in the immediate epoetin alfa group (p  0.0001
FIGURE 3. Linear analogue scale assessment (LASA) overall
quality-of-life scores (last observation carried forward). Base-
line QOL scores were not carried forward. *p  0.01 versus
immediate epoetin alfa group. †p  0.02 versus immediate
epoetin alfa group. ‡p  0.09 versus immediate epoetin alfa
group. §p  0.06 versus immediate epoetin alfa group. De-
layed: Data were analyzed as a whole, irrespective of
whether a patient received epoetin alfa for declining Hb.
Censored analysis (delayed): All measurements taken once a
patient received epoetin alfa were excluded.
FIGURE 4. Hemoglobin (Hb) over time by
treatment group (last observation carried for-
ward). *p  0.0001 versus epoetin alfa group.
Delayed: Data were analyzed as a whole, irre-
spective of whether a patient received epoetin
alfa for declining Hb. Censored analysis (de-
layed): All measurements taken once a patient
received epoetin alfa were excluded.
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between groups). Post hoc analysis revealed that time to Hb
10 g/dl was significantly longer for the immediate epoetin
alfa group than for the delayed group (Figure 5). In the
immediate epoetin alfa and delayed groups, respectively,
anemia (Hb 12 g/dl) was present in 10.4% and 15.4% of
patients at baseline, 24.8% and 73.1% of patients at week 8,
and 25.8% and 60.5% of patients at final measurement
(Figure 6).
FIGURE 5. Kaplan–Meier curve for time to
hemoglobin (Hb) 10 g/dl. *p  0.001 (Fisher’s
exact test).
FIGURE 6. Frequency distribution of hemo-
globin (Hb) strata (last observation carried for-
ward) for (A) immediate epoetin alfa group
and (B) delayed group. Horizontal bars indicate
Hb  12 g/dl.
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Transfusion Incidence
The percentage of patients receiving RBC transfusions
on study was lower in the immediate epoetin alfa group
(11.3%; n  12) than in the delayed group (18.1%; n  19),
although the difference did not reach statistical significance.
The mean time to first RBC transfusion was 65.1 days for the
immediate epoetin alfa group versus 53.2 days for the de-
layed group. Similarly, the percentage of patients receiving
transfusions of any type on study was 12.3% (n  13) in the
immediate epoetin alfa group and 20.0% (n  21) in the
delayed group. No patients in the immediate epoetin alfa
group received RBC transfusions during the first month of the
study, compared with seven patients in the delayed group.
After the first month, rates of transfusion were similar be-
tween the immediate and delayed groups (month 2: n 4 and
n  6, respectively; month 3: n  7 and n  6, respectively;
month 4: n  3 and n  2, respectively; and month 5: n  0
and n  2, respectively). In the censored analysis of the
delayed group (which excluded any transfusion recorded after
a patient received epoetin alfa for declining Hb), 8.6% (n 
9) of patients were transfused.
Tumor Response and Overall Survival
Tumor response rates during the study were similar
between groups (Table 2). The overall response rates (com-
plete response plus partial response) for the immediate epo-
etin alfa group and delayed groups were 29.9% and 21.6%,
respectively. The percentage of patients whose disease pro-
gressed while on study also was similar between groups
(35.6% for the immediate group and 40.9% for the delayed
group).
Median overall survival as shown in Figure 7 was 11.5
months in the immediate epoetin alfa group and 8.3 months in
the delayed group (log rank test; p  0.401). There were six
deaths during the 16-week treatment period in the immediate
epoetin alfa group and five in the delayed group. Causes of
death in these patients included hemorrhage, disease progres-
sion, cardiopulmonary arrest, and sepsis. Eight patients in the
immediate epoetin alfa group and three patients in the de-
layed group were lost to follow-up on retrospective chart
review approximately 1.5 years after study completion. There
was a larger proportion of patients with a baseline ECOG
performance status of 0 or 1 in the immediate epoetin alfa
group versus the delayed group, but an analysis of survival
data for patients with ECOG performance status 0 or 1
showed no difference between groups.
Safety
A total of 215 patients (immediate epoetin alfa group,
n  108; delayed group, n  107) were evaluable for safety.
Mean duration of chemotherapy exposure was 10.6 weeks in
each group. Epoetin alfa was well tolerated. The overall
incidence of adverse events was similar between groups (97%
immediate epoetin alfa group; 95% of delayed group), and
the most common adverse events were nausea and fatigue
(Table 3). The differences in the incidences of dyspnea,
anemia, granulocytopenia, and anxiety was 10% between
treatment groups. Serious adverse events were reported in
39.8% of patients receiving immediate epoetin alfa and in
48.6% of patients in the delayed group. The proportion of
patients who died as a result of an adverse event was similar
between groups (immediate epoetin alfa, 10.2%; delayed,
13.1%). Causes of death for patients who died while on study
were respiratory and/or cardiac failure (n  2), cardiopulmo-
nary arrest (n  3), hemorrhage (n  3), progressive disease
(n  1), and sepsis (n  2). No patients in the immediate
epoetin alfa group and one patient in the delayed group
discontinued the study because of adverse events.
Clinically relevant TVEs—generally defined as blood
clots and emboli, deep thrombophlebitis, cardiac arrest, ce-
rebrovascular incidents, myocardial infarction, and select
arrhythmias—occurred in 13 (12.0%) patients in the imme-
diate epoetin alfa group and in 16 (15.0%) patients in the
delayed group; 11 of the 16 delayed group patients had
developed TVEs after randomization but before the first dose
of epoetin alfa (Table 4). The TVEs reported most frequently
were pulmonary embolism and deep vein thrombosis (nine
and eight events, respectively). Details regarding Hb levels
nearest the time of each event are shown in Table 5. In the
TABLE 2. Tumor Response by Treatment Group
Immediate Epoetin Alfa Delayed*
(n  106) (n  105)
Overall response 26 (29.9) 19 (21.6)
Complete response 1 (1.1) 0 (0.0)
Partial response 25 (28.7) 19 (21.6)
Stable disease 30 (34.5) 33 (37.5)
Progressive disease 31 (35.6) 36 (40.9)
Missing 19 (17.9) 17 (16.2)
*Includes all delayed patients regardless of whether they received delayed epoetin
alfa.
FIGURE 7. Overall survival. Treatment group comparison p
value  0.401 (log rank).
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immediate epoetin alfa group, one patient with an Hb of 18.3
g/dl (study week 14) suffered a cardiopulmonary arrest and
died, and one patient with an Hb of 15.2 g/dl (study week 2)
was hospitalized with a severe case of atrial fibrillation.
Neither event was considered by the investigator to be related
to the study drug. Deep vein thromboses occurred in patients
with Hb levels ranging from 9.6 to 14.0 g/dl. Pulmonary
emboli occurred in patients with Hb levels ranging from 9.8
to 14.0 g/dl. Of note, the dose of epoetin alfa was held or
reduced according to protocol in 15 of 16 patients who had
Hb  15 g/dl on two consecutive evaluations.
Post Hoc Analysis of Delayed Patients
Subsequently Receiving Epoetin Alfa
The original protocol was not designed to analyze
outcomes specifically in the 48 (46%) patients in the delayed
group who received epoetin alfa (including seven patients
who received epoetin alfa despite having Hb 10 g/dl).
However, certain variables such as Hb over time were of
interest and were evaluated post hoc in this patient subgroup.
From the time of first epoetin alfa dose, mean Hb increased
by 1.1 g/dl at week 4 (n  37), 2.0 g/dl at week 8 (n  19),
and 1.7 g/dl at final value (n  48). However, mean Hb at
study end in these patients was notably lower than that of the
immediate epoetin alfa group (11.5 versus 12.9 g/dl, respec-
tively). Because of the small sample size, QOL changes were
not analyzed. Of 46 patients with tumor response data, 8
(17.4%), 18 (39.1%), and 20 (43.5%) patients had a partial
response, stable disease, or progressive disease while on
study, respectively. Five patients were diagnosed with at least
one TVE after initiation of epoetin alfa: two pulmonary
emboli, one atrial fibrillation, two deep thrombophlebitis, one
deep vein thrombosis, and one supraventricular tachycardia.
DISCUSSION
This study demonstrated that QW epoetin alfa initiated
at the start of chemotherapy (“immediate” therapy) effec-
tively maintained Hb in chemotherapy-naı¨ve patients with
advanced NSCLC. In comparison, initiating epoetin alfa only
after Hb decreased to 10 g/dl (“delayed” therapy) resulted
in increases in Hb from the first epoetin alfa dose, but mean
Hb at study end never reached that of patients who received
epoetin alfa at the start of chemotherapy. In addition, there
was a trend towards a reduction in transfusion use in patients
receiving immediate epoetin alfa compared with delayed
treatment, particularly during the first month of the study.
QOL was essentially maintained in both the immediate
and delayed groups; QOL scores declined in both groups, but
the changes were not statistically or clinically significant.30
This modest decline in QOL occurred despite the significant
differences in Hb observed between groups favoring imme-
TABLE 4. Frequency of Clinically Relevant Thrombovascular Events (TVEs) (N  215)
Thrombovascular Event
Immediate Epoetin Alfa,
n (% of patients)*
(n  108)
Delayed, n (% of patients)*
(n  107)
At Any Time Before Epoetin Alfa
Any 13 (12.0) 16 (15.0) 11 (10.3)
Myocardial infarction/cardiac arrest 2 (1.9) 2 (1.9) 2 (1.9)
Embolism pulmonary 3 (2.8) 6 (5.6) 4 (3.7)
Atrial fibrillation paroxysmal/
arrhythmia atrial
2 (1.9) 4 (3.7) 3 (2.8)
Thrombophlebitis deep 1 (0.9) 3 (2.8) 1 (0.9)
Venous thrombosis 1 (0.9) 0 0
Thrombosis venous deep 6 (5.6) 2 (1.9) 1 (0.9)
Embolism/blood clot 0 1 (0.9) 1 (0.9)
Supraventricular tachycardia 0 1 (0.9) 0
*Patients may have had more than one TVE.
TABLE 3. Adverse Events in 15% of Patients (Safety
Population, N  215)
Adverse event, n(%)
Immediate Epoetin
Alfa Group
(n  108)
Delayed Group
(n  107)
Nausea 59 (54.6) 61 (57.0)
Fatigue 57 (52.8) 59 (55.1)
Anorexia 36 (33.3) 31 (29.0)
Constipation 30 (27.8) 39 (36.5)
Diarrhea 30 (27.8) 37 (34.6)
Dyspnea 29 (26.9) 42 (39.3)
Coughing 29 (26.9) 34 (31.8)
Alopecia 28 (25.9) 31 (29.0)
Fever 27 (25.0) 28 (26.2)
Vomiting 24 (22.2) 35 (32.7)
Pain 22 (20.4) 27 (25.2)
Back pain 21 (19.4) 16 (15.0)
Anemia 20 (18.5) 36 (33.6)
Thrombocytopenia 19 (17.6) 21 (19.6)
Myalgia 19 (17.6) 19 (17.8)
Arthralgia 19 (17.6) 17 (15.9)
Granulocytopenia 18 (16.7) 30 (28.0)
Insomnia 18 (16.7) 22 (20.6)
Dizziness 18 (16.7) 9 (8.4)
Chest pain 17 (15.7) 13 (12.2)
Anxiety 8 (7.4) 19 (17.8)
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diate treatment with epoetin alfa. Several factors may have
contributed to this finding. First, the study was originally
powered to detect significant differences in QOL between
groups, but slow enrollment resulted in a smaller sample size
than originally planned and a loss of statistical power. Sec-
ond, baseline LASA scores in the current study were approx-
imately 20 mm higher than previously reported in patients
with lung cancer and anemia enrolled in three large, commu-
nity-based clinical trials evaluating QW or TIW epoetin alfa,
suggesting substantially less QOL impairment at baseline in
the present study.17 Patients in previous studies also tended to
be moderately anemic (mean Hb  9.4 g/dl) at baseline and
could have received multiple cycles of chemotherapy before
enrollment; in comparison, patients were nonanemic (mean
Hb  13.0 g/dl) at baseline and chemotherapy naı¨ve at the
start of the present study. Thus, one possible factor contrib-
uting to the lack of QOL improvements observed in the
current study is that patients in both groups had better QOL
status and higher Hb level at study commencement and, thus,
had a smaller margin for any potential QOL improvement
during the study. Third, although patients in both groups had
impaired QOL at baseline, baseline QOL scores were numer-
ically higher in the immediate epoetin alfa group than in the
delayed group on several scales—possibly leading to even
less room for improvement in QOL in the immediate epoetin
alfa group relative to the delayed group. It is noteworthy,
however, that there was a second imbalance that would have
been expected to actually favor the immediate group: signif-
icantly more patients had ECOG performance status 2 in the
delayed epoetin alfa group, suggesting a higher potential
likelihood of QOL decrement or even lesser improvement in
the delayed group, given their overall lesser health status
compared with the immediate group, thus producing a poten-
tially greater margin of difference between groups. Overall,
these baseline imbalances may have complicated compari-
sons between the groups.
Results from the current (albeit not placebo controlled
or blinded) study did demonstrate trends for Hb level, trans-
fusion use, and QOL that favored immediate epoetin alfa
treatment, and no detrimental effect of immediate epoetin alfa
treatment was seen. Epoetin alfa therapy was well tolerated,
with no notable differences in the type or frequency of
adverse events between groups and no unexpected adverse
events in this population of advanced-stage NSCLC patients
receiving chemotherapy. In addition, overall tumor response
rates and median overall survival were similar between
groups. Thus, to the extent that we could evaluate it in our
study, there was no evidence to suggest that survival was
shortened in patients with advanced-stage NSCLC who re-
ceived epoetin alfa at the start of chemotherapy (immediate
group) compared with patients receiving epoetin alfa after
anemia developed (delayed group) (Figure 7).
In previous studies of patients with various tumor types
(including lung cancer) receiving chemotherapy, low Hb
levels have been associated with poorer response and surviv-
al.10,31–33 For example, a retrospective analysis of 694
NSCLC patients treated with combined modality therapy in
five recently reported CALGB trials showed significantly
poorer survival (p  0.0001) among NSCLC patients with
baseline Hb 12 g/dl compared with those with Hb 12
g/dl.10 Further, data from a prospective, multicenter, random-
ized, double-blind trial of 150 to 300 U/kg of epoetin alfa
TIW versus placebo in 375 patients with solid tumors or
hematologic malignancies receiving nonplatinum chemother-
apy suggested a trend toward improved overall survival,
favoring epoetin alfa.15 The protocol was not originally pow-
ered to assess survival, however, and did not control for
variables that may have affected survival (e.g., disease stage,
bone marrow involvement, chemotherapy intensity, disease
progression).
To prospectively test the hypothesis that survival may
be improved by maintaining Hb within the normal range (12
to 14 g/dl) with QW epoetin alfa during first-line chemother-
apy for metastatic breast cancer, a double-blind, randomized,
placebo-controlled study was recently undertaken in Europe.
The study was terminated early because of significantly
higher mortality in the epoetin alfa group compared with the
placebo group (p  0.0117).24 The trial investigators noted
that the study design had a number of limitations that made
these results difficult to interpret, including that fact that the
study was not designed to prospectively assess several prog-
nostic factors that may have contributed to differences in
survival between the two groups. Thus, the effect of eryth-
ropoietic agents on survival remains a controversial issue. A
TABLE 5. Hemoglobin at Time of Clinically Relevant Thrombovascular Event (TVE)
Immediate Epoetin Alfa
(N  13)
Delayed
At Any Time
(N  16)
Before Epoetin Alfa
(N  11)
Hb Nearest Event n* No. of events n* No. of events n* No. of events
10.0 g/dl — — 4 6 — —
10.1–12.0 g/dl 2 2 8 9 7 8
12.1–14.0 g/dl 9 11 5 5 4 5
14.0 g/dl 2 2 — — —
Hb range (g/dl) 11.3–18.3 9.6–13.9 10.2–13.9
Hb, hemoglobin.
*Patients with multiple events may be included in more than one Hb category.
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recent meta-analysis by Bohlius et al.34,35 shows no firm
conclusions regarding the relationship between erythropoietic
therapy and survival.
Thrombovascular events have been reported at greater
frequency in patients receiving erythropoietic agents,34–36 but
the mechanism and relationship to Hb level remains unclear.
In recent years, meta-analyses of randomized trials have
provided estimates of the associated impact of erythropoietic
agents on the incidence of TVEs in the cancer popula-
tion.34,35,37 An initial publication by Bohlius et al.37 identified
a nonsignificant relative risk of 1.57 (95% confidence inter-
val, 0.94 to 2.66) for erythropoietin-treated versus untreated
patients developing a TVE. However, a more recent update
involving a larger number of trials reported a statistically
significant relative risk of 1.67 (95% confidence interval, 1.35
to 2.06).34,35 In the current trial, TVEs occurred in 13 patients
in the immediate group (15 unique events) and 16 patients in
the delayed group (19 unique events). Of note, 11 patients in
the delayed group had TVEs before epoetin alfa therapy
commenced, demonstrating the increased potential for TVEs
in this population, and the difficulty in assigning causality of
a TVE in an individual patient receiving an erythropoietic
agent. Clearly, further preclinical and clinical research is
needed in this area. In the meantime, on the basis of these
survival and TVE findings and other investigational studies,
until further information is available, the labeling for epoetin
alfa and other erythropoietic agents in the same class was
revised to recommend a target Hb not exceeding 12 g/dl for both
men and women and also recommending against increases in Hb
greater than 1 g/dl within any 2-week period.38,39
In conclusion, despite loss of statistical power for the
primary endpoint as a result of early termination of accrual,
the current study demonstrated that early treatment with
epoetin alfa is safe in this population and is effective in
maintaining Hb and reducing transfusions in chemotherapy-
naı¨ve patients with advanced-stage NSCLC and Hb levels
11 g/dl. However, this investigational use of epoetin alfa
requires validation before the present clinical practice guide-
lines and current prescribing information38 can be amended.
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